Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The EUROPA trial: design, baseline demography and status of the substudies.

Gomma AH, Fox KM.

Cardiovasc Drugs Ther. 2001 Mar;15(2):169-79.

PMID:
11669411
2.

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators..

Lancet. 2003 Sep 6;362(9386):782-8.

PMID:
13678872
3.

Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.

Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML; EUROPA investigators..

Int J Cardiol. 2007 Sep 14;121(1):57-61. Epub 2007 Jan 31.

PMID:
17270296
4.
5.

PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design.

Bots ML, Remme WJ, Lüscher TF, Grobbee DE; EUROPA-PERFECT Investigators..

Cardiovasc Drugs Ther. 2002 May;16(3):227-36.

PMID:
12374901
6.

The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).

Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML.

Eur Heart J. 1998 Sep;19 Suppl J:J52-5.

PMID:
9796841
7.
8.

PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.

Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators..

Cardiovasc Drugs Ther. 2003 Jan;17(1):83-91.

PMID:
12843690
9.

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy.

Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML; EUROPA Investigators..

Eur Heart J. 2005 Jul;26(14):1369-78. Epub 2005 Apr 28.

PMID:
15860521
10.

[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].

Ferrari R, Papa K, Bernocchi P, Gimbatti OJ, Golcea SS, Bettini A, Ceconi C.

Ital Heart J. 2005 Nov;6 Suppl 7:24S-32S. Review. Italian.

PMID:
16485514
11.

[Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].

Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.

Ital Heart J. 2005 Nov;6 Suppl 7:14S-23S. Review. Italian.

PMID:
16485513
12.

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.

Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, Kluft C, Blann A, Cokkinos D, Ferrari R; EUROPA Investigators.; PERTINENT Investigators and the Statistical Committee..

Cardiovasc Res. 2007 Jan 1;73(1):237-46. Epub 2006 Nov 10.

PMID:
17140552
13.

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.

Bots ML, Remme WJ, Lüscher TF, Fox KM, Bertrand M, Ferrari R, Simoons ML, Grobbee DE; EUROPA-PERFECT Investigators..

Cardiovasc Drugs Ther. 2007 Aug;21(4):269-79.

14.

EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.

Simoons ML, Vos J, de Feyter PJ, Bots ML, Remme WJ, Grobbee DE, Kluft C, de Maat MP, Fox KM, Deckers JW.

Eur Heart J. 1998 Sep;19 Suppl J:J56-60. Review.

PMID:
9796842
15.
16.

VALIANT and EUROPA.

Liebson PR.

Prev Cardiol. 2004 Winter;7(1):42-4. No abstract available.

17.

Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.

Briggs A, Mihaylova B, Sculpher M, Hall A, Wolstenholme J, Simoons M, Deckers J, Ferrari R, Remme WJ, Bertrand M, Fox K; EUROPA Trial Investigators..

Heart. 2007 Sep;93(9):1081-6. Epub 2006 Nov 29.

18.

Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial.

Bertrand ME, Fox KM, Remme WJ, Ferrari R, Simoons ML.

Arch Cardiovasc Dis. 2009 Feb;102(2):89-96. doi: 10.1016/j.acvd.2008.10.012. Epub 2009 Jan 19.

19.

EUROPA: has anything new been learned with angiotensin-converting enzyme inhibitors?

Sica DA.

J Clin Hypertens (Greenwich). 2004 Feb;6(2):91-5. Review.

20.

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.

Brugts JJ, de Maat MP, Boersma E, Witteman JC, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrari R, Danser AH, Simoons ML; EUROPA-PERGENE investigators..

Cardiovasc Drugs Ther. 2009 Apr;23(2):171-81. doi: 10.1007/s10557-008-6156-1. Epub 2008 Dec 10.

PMID:
19082699

Supplemental Content

Support Center